Nicola Lucio Liberato
Affiliation: Ospedale Civile
- Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancerNicola Lucio Liberato
Azienda Ospedaliera della Provincia di Pavia, Divisione di Medicina Interna, Ospedale Civile, Casorate Primo, Pavia, Italy
J Clin Oncol 25:625-33. 2007..To evaluate the cost-effectiveness of 12-month adjuvant trastuzumab therapy in women with high-risk human epidermal growth factor receptor 2 (HER2) -positive early breast cancer...
- Adding docetaxel to cisplatin and fluorouracil in patients with unresectable head and neck cancer: a cost-utility analysisN L Liberato
Department of Internal Medicine, Azienda Ospedaliera della Provincia di Pavia, Casorate Primo, Italy
Ann Oncol 23:1825-32. 2012..The aim of the study was to analyze the cost-utility of TPF in patients with unresectable disease...
- Clinical and economic issues in the treatment of advanced breast cancer with bisphosphonatesNicola Lucio Liberato
Division of Internal Medicine, Civil Hospital, Voghera, Italy
Drugs Aging 20:631-42. 2003..Probably, country- and drug-specific policies might increase the efficiency of this treatment. Further outcomes research is required to assess these agents more fully...